Italia markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,9000+0,0400 (+2,15%)
Alla chiusura: 04:00PM EDT
1,8100 -0,09 (-4,74%)
Dopo ore: 05:17PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,8600
Aperto1,9100
Denaro1,4500 x 3000
Lettera2,0900 x 1400
Min-Max giorno1,9000 - 1,9900
Intervallo di 52 settimane1,3720 - 16,8000
Volume8.158
Media Volume35.077
Capitalizzazione6,352M
Beta (5 anni mensile)0,40
Rapporto PE (ttm)N/D
EPS (ttm)-2,3400
Prossima data utili08 mag 2023 - 12 mag 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A7,00
  • GlobeNewswire

    Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023

    Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI Image 1 All-Cause HCRU in the Pre-nasal MCP period vs. Post-nasal MCP period Image 2 Nausea, Vomiting, and DGP-associated HCRU in the Pre-nasal MCP period vs. Post-nasal MCP Period SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclo

  • GlobeNewswire

    Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

    Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31,

  • GlobeNewswire

    Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

    SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes. Management will host a conference call on Tuesday, March 21, 2023, at 4:30 p.m. ET